Skip to main content
logo
Liminatus Pharma, Inc. (LIMN)
NASDAQ: LIMN · Real-Time Price · USD
0.1800
-0.0040 (-2.17%)
At close: May 15, 2026, 4:00 PM EDT
0.1877
+0.0077 (4.28%)
After-hours: May 15, 2026, 7:49 PM EDT

Company Description

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States.

It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.

The company was founded in 2018 and is based in Cerritos, California.

Liminatus Pharma, Inc.
Liminatus Pharma logo
CountryUnited States
Founded2018
IndustryBiotechnology
SectorHealthcare
Employees1
CEOChris Kim

Contact Details

Address:
12611 Hiddencreek Way, Unit C
Cerritos, California 90703
United States
Phone213 273 5453
Websiteliminatuspharma.com

Stock Details

Ticker SymbolLIMN
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001831874
CUSIP Number53271X116
ISIN NumberUS53271X1081
SIC Code6770

Key Executives

NamePosition
Chris Kim J.D., L.L.M.Chief Executive Officer and Chairman
Scott DamChief Financial Officer
Dr. Beom Kyu ChoiChief Technology Officer and Member of Scientific Advisory Board
Dr. Byong Chul Yoo Ph.D.Chief Science Officer and Member of Scientific Advisory Board
Dr. Sang-jin Lee Ph.D.Head of Research and Development and Member of Scientific Advisory Board

Latest SEC Filings

DateTypeTitle
Apr 30, 202515-12GSecurities registration termination
Apr 16, 202510-KAnnual Report
Mar 31, 2025NT 10-KNotification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Mar 10, 20258-KCurrent Report
Mar 5, 202525-NSEFiling
Feb 7, 2025DEFM14AFiling
Jan 28, 2025425Filing
Jan 28, 20258-KCurrent Report
Jan 16, 2025425Filing
Jan 16, 20258-KCurrent Report
View All SEC Filings